<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Tuberculosis is an airborne infectious disease that remains a huge global health-related issue nowadays. Despite constant approvals of newly developed drugs, the use of first-line antituberculosis medicines seems reasonable in drug-susceptible <italic>Mycobacterium tuberculosis</italic> strains. Therapeutic drug monitoring presents a useful technique for the determination of plasma drug concentration to adjust appropriate dose regimes. In tuberculosis treatment, therapeutic drug monitoring is aiding clinicians in selecting an optimal therapeutic level, which is essential for the personalisation of therapy. This review is aimed at clarifying the use of therapeutic drug monitoring of the first-line antituberculosis drugs in routine clinical practice.</p>
</abstract>

Tuberculosis is an airborne infectious disease that remains a huge global health-related issue nowadays. Despite constant approvals of newly developed drugs, the use of first-line antituberculosis medicines seems reasonable in drug-susceptible Mycobacterium tuberculosis strains. Therapeutic drug monitoring presents a useful technique for the determination of plasma drug concentration to adjust appropriate dose regimes. In tuberculosis treatment, therapeutic drug monitoring is aiding clinicians in selecting an optimal therapeutic level, which is essential for the personalisation of therapy. This review is aimed at clarifying the use of therapeutic drug monitoring of the first-line antituberculosis drugs in routine clinical practice.

Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs

Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine in Martin

Comenius University in Bratislava, and Martin University Hospital

Acta Medica Martiniana

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs"}

Tuberculosis is an airborne infectious disease that remains a huge global health-related issue nowadays. Despite constant approvals of newly developed drugs,...

Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs

Online veröffentlicht: 20. Aug. 2020

Seitenbereich: 45 - 55

Eingereicht: 29. Apr. 2020

Akzeptiert: 28. Mai 2020

DOI: https://doi.org/10.2478/acm-2020-0006

Schlüsselwörter
first-line antituberculosis drugs, therapeutic drug monitoring, isoniazid, rifampicin, ethambutol, pyrazinamide

© 2020 K Prso et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs

Online veröffentlicht: 20. Aug. 2020

Seitenbereich: 45 - 55

Eingereicht: 29. Apr. 2020

Akzeptiert: 28. Mai 2020

DOI: https://doi.org/10.2478/acm-2020-0006

Schlüsselwörterfirst-line antituberculosis drugs, therapeutic drug monitoring, isoniazid, rifampicin, ethambutol, pyrazinamide

© 2020 K Prso et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Schlüsselwörter
first-line antituberculosis drugs, therapeutic drug monitoring, isoniazid, rifampicin, ethambutol, pyrazinamide